Inhibrx Biosciences reports positive Phase 2 results for head and neck cancer therapy
Inhibrx Biosciences said its INBRX-106 in combination with pembrolizumab produced positive results in a Phase 2 study for metastatic or unresectable recurrent head and neck squamous cell carcinoma.
Inhibrx Biosciences reported positive results from a Phase 2 study of a potential treatment for metastatic or unresectable recurrent head and neck squamous cell carcinoma. The clinical-stage biopharmaceutical company said Tuesday its INBRX-106 drug in combination with pembrolizumab d…